DEpletion of Serum amyloid P component In Alzheimer's Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer's disease.

Trial Profile

DEpletion of Serum amyloid P component In Alzheimer's Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer's disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs GSK 2315698 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms DESPIAD
  • Most Recent Events

    • 02 Aug 2017 Last checked against ISRCTN: Current Controlled Trials record.
    • 02 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 24 May 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top